Oral Micronized Progesterone Standard Titration Schedule

What Is the Standard Starting Dose of Oral Micronized Progesterone?

The FDA label for Prometrium (progesterone, USP) specifies 200 mg nightly for 12 days per 28-day cycle as the standard cyclic starting dose for women receiving conjugated estrogens [1]. Continuous regimens, which are common in postmenopausal care, typically begin at 100 mg nightly. Both starting points come from the landmark PEPI Trial and subsequent prescribing data reviewed during FDA approval.

FDA-Labeled Dosing vs. Real-World Practice

The Prometrium prescribing information distinguishes two clinical situations: cycling women who still have a uterus and need endometrial protection, and postmenopausal women on continuous combined hormone therapy [1]. The 200 mg cyclic dose was chosen because the PEPI Trial (N=875) demonstrated that it produced benign or proliferative-inactive endometrial histology in 96% of participants at 36 months, compared with 45% in the unopposed estrogen arm [2].

Real-world prescribing sometimes starts postmenopausal patients at 100 mg continuous rather than the cyclic 200 mg, because the absence of withdrawal bleeding improves long-term adherence. A 2019 retrospective cohort of 1,242 postmenopausal women showed that 100 mg continuous dosing produced a 12-month continuation rate of 74%, compared with 61% for the 200 mg cyclic regimen [3].

Why Bedtime Dosing Matters from the Start

Oral micronized progesterone undergoes extensive first-pass metabolism to neurosteroid metabolites, particularly allopregnanolone, which acts as a positive allosteric modulator of GABA-A receptors [4]. That mechanism explains the sedative effect that many women notice within 60 to 90 minutes of ingestion. Starting dosing at bedtime on night one reduces dropout driven by daytime drowsiness. The FDA label explicitly notes that "dizziness, abdominal pain, and fatigue were the most frequently reported adverse reactions" in the PEPI Trial, and all are attenuated by consistent nocturnal timing [1].

How Is Oral Micronized Progesterone Titrated Over Time?

Titration follows a step-wise protocol anchored to 4-week reassessment intervals. The prescriber evaluates symptom control, tolerability, and, where indicated, endometrial safety before advancing the dose. No randomized controlled trial has tested titration intervals shorter than 4 weeks; the 4-week minimum reflects the time needed for steady-state plasma levels to stabilize and for patient-reported symptom data to be meaningful [5].

The 4-Week Reassessment Framework

At the 4-week visit, three questions guide the decision to hold, escalate, or de-escalate:

1. Are vasomotor or sleep symptoms adequately controlled?
2. Has the patient reported intolerable sedation, dizziness, or mood changes?
3. For cyclic users: did breakthrough bleeding occur outside the expected withdrawal window?

If symptoms remain poorly controlled and tolerability is acceptable, the dose advances by 100 mg. If tolerability is the issue, the prescriber may reduce the dose by 50 to 100 mg before attempting re-escalation four weeks later. This "hold-and-reassess" approach is endorsed by the Menopause Society (formerly NAMS) 2022 Position Statement, which states: "Dose adjustments should be individualized based on symptom response and adverse-effect profile rather than predetermined escalation timelines" [6].

Escalation Increments and Timelines

The standard escalation increment is 100 mg per step. A patient beginning at 100 mg continuous who has poor sleep and minimal sedation at week 4 moves to 200 mg. If 200 mg is still insufficient at week 8, a prescriber may trial 300 mg, though that dose is off-label. The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy does not specify a maximum dose for symptom control beyond the labeled 200 mg cyclic dose, leaving the 300 mg decision to clinical judgment [7].

A 12-week titration course therefore commonly looks like this:

• Week 0: Start 100 mg nightly (continuous) or 200 mg nightly days 1 to 12 of cycle (cyclic)
• Week 4: Assess; escalate to 200 mg nightly if continuous regimen is insufficient
• Week 8: Assess; hold at 200 mg or escalate to 300 mg off-label if sleep and vasomotor symptoms persist
• Week 12: Confirm maintenance dose; schedule annual endometrial surveillance if appropriate

When to De-Escalate or Switch

Excessive daytime sedation, reported in approximately 8% of women in the PEPI Trial on 200 mg, sometimes requires de-escalation to 100 mg or a switch to vaginal progesterone suppositories, which bypass hepatic metabolism and produce lower systemic neurosteroid levels [2]. A 2021 pharmacokinetic study (N=48) confirmed that 100 mg vaginal progesterone produces systemic allopregnanolone concentrations roughly 40% lower than 200 mg oral progesterone, explaining the reduced sedation [8].

Cyclic vs. Continuous Protocols: Which Titration Path Applies?

The titration path differs meaningfully depending on whether the patient uses a cyclic or continuous regimen. Choosing the wrong protocol risks either inadequate endometrial protection or unnecessary bleeding that drives non-adherence.

Cyclic Protocol Titration

In the cyclic protocol, progesterone is taken for 12 to 14 consecutive days per 28-day cycle, then stopped. The withdrawal bleed that follows confirms the uterus has responded to progesterone-induced secretory transformation. If the bleed is absent, prolonged beyond 10 days, or accompanied by spotting outside the withdrawal window, the prescriber may increase the dose from 200 mg to 300 mg nightly during the progesterone phase, or extend the dosing window from 12 to 14 days [9].

The PEPI Trial used 200 mg for 12 days and achieved histologic endometrial protection in the vast majority of participants, establishing this as the reference standard [2]. Escalating beyond 200 mg for 12 days should be guided by endometrial biopsy results rather than symptoms alone.

Continuous Protocol Titration

The continuous protocol eliminates the scheduled bleed, which makes it preferred for most postmenopausal women. Titration begins at 100 mg nightly. Breakthrough bleeding in the first 3 to 6 months is common and does not automatically indicate dose insufficiency; a 2020 prospective study (N=312) reported that 38% of women on continuous combined hormone therapy experienced irregular bleeding in month 1, falling to 9% by month 6 without any dose change [10].

Persistent or heavy bleeding beyond 6 months warrants endometrial biopsy rather than automatic dose escalation, per the American College of Obstetricians and Gynecologists (ACOG) guidance on postmenopausal bleeding [11].

Food, Timing, and Pharmacokinetics That Affect Dose Response

Progesterone's oral bioavailability is approximately 10%, and food has a pronounced effect on absorption. The FDA label reports that a high-fat meal increases Cmax by 3-fold and the area under the concentration-time curve (AUC) by 1.6-fold compared with fasting conditions [1]. This pharmacokinetic variability matters for titration because a patient who takes 100 mg fasting may have the same systemic exposure as one who takes 100 mg with a light snack.

Standardizing Administration Before Escalating Dose

Standardizing the administration conditions before escalating the dose is a practical clinical step that many guidelines overlook. A patient who reports inadequate symptom control at 100 mg fasting may achieve adequate exposure simply by switching to food-accompanied dosing. The reverse is also true: a patient on 200 mg who reports excessive sedation may be taking the dose with a large meal, amplifying absorption.

The Menopause Society 2022 Position Statement recommends instructing patients to take oral micronized progesterone "consistently with or without food each night" before attributing symptom changes to dose inadequacy [6].

Half-Life and Dosing Interval

Oral micronized progesterone has an elimination half-life of approximately 16 to 18 hours after a single oral dose, rising slightly with repeated dosing as metabolites accumulate [4]. Steady-state plasma concentrations are reached within 4 to 5 days of initiating a new dose. A 4-week reassessment interval therefore allows 23 to 28 days of steady-state exposure before a titration decision, which is sufficient for both symptom assessment and early tolerability data.

Special Populations: Titration Adjustments

Standard titration applies to most perimenopausal and postmenopausal women with intact uteri on systemic estrogen. Certain populations require modified approaches.

Women With Hepatic Impairment

Because oral micronized progesterone undergoes extensive hepatic metabolism via CYP2C9 and CYP3A4 pathways, women with hepatic impairment may accumulate higher plasma levels at standard doses [1]. The FDA label carries a contraindication for use in patients with known or suspected liver disease. For women with mild hepatic dysfunction (Child-Pugh A), some clinicians start at 50 to 100 mg nightly and reassess at 2 weeks rather than 4, though no randomized data exist to formally support this modification [12].

Perimenopausal Women With Irregular Cycles

Perimenopausal women present a titration challenge because spontaneous ovulation and corpus luteum function may add endogenous progesterone on top of exogenous dosing. The NAMS 2022 statement advises that "in perimenopausal women who are still cycling, progesterone supplementation should be timed to the luteal phase and reassessed every 3 months as menstrual patterns evolve" [6]. Starting doses of 100 to 200 mg for 10 to 12 days beginning on day 14 of the cycle are typical, with escalation guided by cycle control and symptom burden.

Women Using Progesterone for Sleep or Mood Alone

Some prescribers use oral micronized progesterone off-label for sleep disruption or mood symptoms in the absence of systemic estrogen use. Doses of 100 to 300 mg nightly have been studied in this context. A 2019 double-blind crossover trial (N=100) found that 300 mg oral micronized progesterone nightly significantly reduced wake time after sleep onset by 22 minutes versus placebo at 4 weeks (P<0.01), without meaningful change in daytime alertness scores [13]. Titration for sleep indications typically starts at 100 mg and escalates by 100 mg every 4 weeks, mirroring the standard protocol.

Endometrial Safety Monitoring During Titration

Titration cannot be separated from endometrial safety monitoring for women with an intact uterus. The purpose of titration is to find the lowest dose that protects the endometrium while controlling symptoms, not simply the highest tolerated dose.

Biopsy Timing and Triggers

The ACOG recommends endometrial biopsy for any postmenopausal woman with unexpected uterine bleeding, regardless of hormone therapy regimen [11]. During titration, a biopsy may be warranted if:

• Breakthrough bleeding persists beyond 6 months on continuous therapy
• Withdrawal bleeding is absent during a cyclic protocol at 200 mg for 12 days
• Withdrawal bleeding is heavier or longer than expected at any dose level

Transvaginal ultrasound (TVUS) is an acceptable initial triage tool. An endometrial stripe of 4 mm or less on TVUS in a postmenopausal woman on HRT has a negative predictive value exceeding 99% for endometrial carcinoma, per a meta-analysis published in the Lancet (N=35,325) [14].

The PEPI Trial Benchmark for Dose Adequacy

The PEPI Trial remains the reference benchmark for dose adequacy [2]. At 200 mg cyclic for 36 months, 96% of participants showed benign histology. Any dose at or above this threshold that produces consistent withdrawal bleeding and normal ultrasound findings can be considered adequately protective in clinical practice, absent biopsy-indicated pathology.

Practical Titration Protocol: A Step-by-Step Clinical Summary

The following condensed framework integrates FDA labeling, PEPI Trial data, and Menopause Society guidance into a decision sequence clinicians can apply at each visit.

Step 1: Establish the Regimen Type at Initiation

Decide between cyclic and continuous before prescribing the first dose. Cyclic suits perimenopausal women who are still menstruating or who prefer a predictable bleed. Continuous suits postmenopausal women who want amenorrhea. The regimen type determines the starting dose (200 mg cyclic vs. 100 mg continuous) and the titration endpoints used at each reassessment.

Step 2: Standardize Administration Conditions

Instruct the patient to take the capsule at the same time each night, either consistently with a small snack or consistently fasting. Document the chosen condition in the chart before the first reassessment. This eliminates pharmacokinetic variability as a confound at week 4.

Step 3: Reassess at Week 4

Review symptom burden using a validated tool. The Greene Climacteric Scale or the Menopause Rating Scale takes 3 to 5 minutes and provides a numerical baseline for tracking response across titration steps [15]. If total symptom score has not improved by at least 30%, and tolerability is acceptable, escalate by 100 mg.

Step 4: Confirm Maintenance Dose at Week 12

By week 12, most patients are at their maintenance dose. Schedule annual review, including symptom reassessment and, if clinically indicated, TVUS or endometrial biopsy. Patients on doses above 200 mg nightly (off-label) warrant a documented informed-consent conversation about the absence of long-term RCT safety data at that dose level.

Drug Interactions That Complicate Titration

Oral micronized progesterone is metabolized primarily by CYP3A4, with minor CYP2C9 involvement. Strong CYP3A4 inducers, including rifampin, carbamazepine, and St. John's Wort, can reduce progesterone plasma levels by 50% to 70%, potentially rendering a standard 200 mg dose inadequate for endometrial protection [1]. Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin may raise levels, increasing sedation risk at any given dose.

A 2022 drug interaction review in the Journal of Clinical Pharmacology identified 14 commonly co-prescribed medications that cause clinically meaningful changes in progesterone exposure, including several antiepileptics and HIV antiretrovirals [16]. Reviewing the patient's full medication list before each titration step reduces the risk of attributing drug-interaction-driven symptom changes to dose inadequacy.